PALVELLA THERAPEUTICS INC (PVLA)
Sector: Health Care
2026 Annual Meeting Analysis
PALVELLA THERAPEUTICS INC · Meeting: June 10, 2026
Directors FOR
3
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class III Directors for a Three-Year Term Expiring in 2029
Jenkins joined the board in December 2024 (less than 24 months ago), making him exempt from the TSR trigger under policy; he has relevant healthcare investment and executive leadership experience, chairs the Audit Committee, and the proxy discloses no overboarding, attendance, independence, or familial relationship concerns.
Davis joined the board in December 2024 (less than 24 months ago), making him exempt from the TSR trigger; he is a sitting CEO (of Ligand Pharmaceuticals) but holds only two public board seats total (Ligand and Pelthos Therapeutics, plus PVLA), which is within the policy limit for sitting CEOs; he has deep biopharma industry and investment experience, and no attendance, independence, or familial relationship concerns are present.
Doux joined the board in April 2026 (well within the 24-month new-director exemption from the TSR trigger); he is a board-certified dermatologist with directly relevant disease-area expertise for a rare skin disease company, holds no other public board seats, and no attendance, independence, or familial relationship concerns apply.
All three Class III nominees receive a FOR vote. The company's 3-year price return of +107.0% outperforms the XBI — SPDR S&P Biotech ETF's 3-year return of +60.9% by +46.1 percentage points, well below the 65-percentage-point threshold required to trigger a TSR-based against vote for strong positive performers; additionally, all three nominees joined the board within the past 24 months, making them individually exempt from the TSR trigger. No overboarding, attendance, independence, or familial relationship issues were identified.
Say on Pay
✓ FORCEO
Wesley H. Kaupinen
Total Comp
$3,404,904
Prior Support
99.1%%
CEO total compensation of $3,404,904 — consisting of $575,000 base salary, $2,469,886 in stock option awards, and $359,375 in annual performance bonus — is reasonable for the CEO of a clinical-stage biotech company at a $1.8 billion market cap, and the pay mix is heavily weighted toward variable equity compensation (roughly 73% of total pay), well above the 50-60% variable pay threshold the policy requires. The pay-for-performance alignment check is satisfied: the company's stock returned +428.5% over one year and +107.0% over three years, significantly outpacing the XBI — SPDR S&P Biotech ETF's +58.9% and +60.9% returns respectively, demonstrating that above-benchmark incentive awards reflect genuine shareholder value creation. The company received 99.1% shareholder support on Say on Pay at the 2025 annual meeting, a clawback policy is disclosed, and no governance concerns around pay structure were identified.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
8 yrs
Audit Fees
$643,000
Non-Audit Fees
$0
EY has served since 2018 (approximately 8 years), well below the 25-year tenure threshold; in 2025, non-audit fees were zero — EY charged only core audit fees of $643,000 — so the non-audit fee ratio is 0%, far below the 50% threshold; EY is a Big 4 firm appropriate for a $1.8 billion market cap company; no material restatements were identified.
Overall Assessment
The 2026 Palvella Therapeutics annual meeting ballot is straightforward with no major governance concerns: all three Class III director nominees are recently appointed, qualified, and benefit from the 24-month new-director TSR exemption; the stock has dramatically outperformed the XBI — SPDR S&P Biotech ETF benchmark; EY's audit engagement is clean with zero non-audit fees; and the CEO's compensation structure is heavily performance-linked with strong shareholder support from the prior year. The only non-standard items are an equity plan share increase and a linked adjournment proposal, both of which fall outside the current scope of the voting policy.